Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]M. P. Cotter, R. W. Gern, G. Y. Ho, R. Y. Chang and R. D. Burk: Role of family history and ethnicity on the mode and age of prostate cancer presentation. Prostate, 50(4), 216-21 (2002)

  • [2]R. M. Hoffman, F. D. Gilliland, J. W. Eley, L. C. Harlan, R. A. Stephenson, J. L. Stanford, P. C. Albertson, A. S. Hamilton, W. C. Hunt and A. L. Potosky: Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst, 93(5), 388-95 (2001)

  • [3]E. A. Platz, E. B. Rimm, W. C. Willett, P. W. Kantoff and E. Giovannucci: Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst, 92(24), 2009-17 (2000)

  • [4]C. Desantis, D. Naishadham and A. Jemal: Cancer statistics for African Americans, 2013. CA Cancer J Clin (2013)

  • [5]H. Gronberg: Prostate cancer epidemiology. Lancet, 361(9360), 859-64 (2003)

  • [6]D. J. Schaid: The complex genetic epidemiology of prostate cancer. Hum Mol Genet, 13 Spec No1, R103-21 (2004)

  • [7]X. L. Du, S. Fang, A. L. Coker, M. Sanderson, C. Aragaki, J. N. Cormier, Y. Xing, B. J. Gor and W. Chan: Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer, 106(6), 1276-85 (2006)

  • [88]S. Reddy, M. Shapiro, R. Morton, Jr. and O. W. Brawley: Prostate cancer in black and white Americans. Cancer Metastasis Rev, 22(1), 83-86 (2003)

  • [99]A. S. Robbins, A. S. Whittemore and D. H. Thom: Differences in socioeconomic status and survival among white and black men with prostate cancer. Am J Epidemiol, 151(4), 409-16 (2000)

  • [10]I. J. Powell: Prostate cancer in the African American: is this a different disease? Semin Urol Oncol, 16(4), 221-6(1998)

  • [11]A. S. Robbins, A. S. Whittemore and S. K. Van Den Eeden: Race, prostate cancer survival, and membership in a large health maintenance organization. J Natl Cancer Inst, 90(13), 986-90 (1998)

  • [12]P. E. Li and P. S. Nelson: Prostate cancer genomics. Curr Urol Rep, 2(1), 70-8 (2001)

  • [13]D. Karan, M. F. Lin, S. L. Johansson and S. K. Batra: Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer, 103(3), 285-93 (2003)

  • [14]C. A. Heinlein and C. Chang: Androgen receptor in prostate cancer. Endocr Rev, 25(2), 276-308 (2004)

  • [15]K. E. Gaston, D. Kim, S. Singh, O. H. Ford, 3rd and J. L. Mohler: Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol, 170(3), 990-3 (2003)

  • [16]A. Edwards, H. A. Hammond, L. Jin, C. T. Caskey and R. Chakraborty: Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics, 12(2), 241-53 (1992)

  • [17]N. L. Chamberlain, E. D. Driver and R. L. Miesfeld: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res, 22(15), 3181-6 (1994)

  • [18]E. Giovannucci, M. J. Stampfer, K. Krithivas, M. Brown, D. Dahl, A. Brufsky, J. Talcott, C. H. Hennekens and P. W. Kantoff: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A, 94(7), 3320-3 (1997)

  • [19]D. O. Hardy, H. I. Scher, T. Bogenreider, P. Sabbatini, Z. F. Zhang, D. M. Nanus and J. F. Catterall: Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab, 81(12), 4400-5 (1996)

  • [20]E. A. Platz, E. Giovannucci, D. M. Dahl, K. Krithivas, C. H. Hennekens, M. Brown, M. J. Stampfer and P. W. Kantoff: The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 7(5), 379-84 (1998)

  • [21]S. A. Ingles, R. K. Ross, M. C. Yu, R. A. Irvine, G. La Pera, R. W. Haile and G. A. Coetzee: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst, 89(2), 166-70 (1997)

  • [22]J. L. Stanford, J. J. Just, M. Gibbs, K. G. Wicklund, C. L. Neal, B. A. Blumenstein and E. A. Ostrander: Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res, 57(6), 1194-8 (1997)

  • [23]O. Sartor, Q. Zheng and J. A. Eastham: Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology, 53(2), 378-80 (1999)

  • [24]R. A. Irvine, M. C. Yu, R. K. Ross and G. A. Coetzee: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res, 55(9), 1937-40 (1995)

  • [25]C. W. Gregory, R. T. Johnson, Jr., S. C. Presnell, J. L. Mohler and F. S. French: Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. J Androl, 22(4), 537-48 (2001)

  • [26]C. W. Gregory, D. Kim, P. Ye, A. J. D’Ercole, T. G. Pretlow, J. L. Mohler and F. S. French: Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology, 140(5), 2372-81 (1999)

  • [27]D. J. Hryb, A. M. Nakhla, S. M. Kahn, J. St George, N. C. Levy, N. A. Romas and W. Rosner: Sex hormone-binding globulin in the human prostate is locally synthesized and may act as an autocrine/paracrine effector. J Biol Chem, 277(29), 26618-22 (2002)

  • [28]J. L. Mohler, T. L. Morris, O. H. Ford, 3rd, R. F. Alvey, C. Sakamoto and C. W. Gregory: Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate, 51(4), 247-55 (2002)

  • [29]A. Wolk, S. O. Andersson and R. Bergstrom: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst, 89(11), 820 (1997)

  • [30]K. J. Pienta, J. A. Goodson and P. S. Esper: Epidemiology of prostate cancer: molecular and environmental clues. Urology, 48(5), 676-83 (1996)

  • [31]A. W. Meikle and J. A. Smith, Jr.: Epidemiology of prostate cancer. Urol Clin North Am, 17(4), 709-18 (1990)

  • [32]N. M. Makridakis and J. K. Reichardt: Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol Rev, 23(1), 24-9 (2001)

  • [33]L. Ellis and H. Nyborg: Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids, 57(2), 72-5 (1992)

  • [34]R. Ross, L. Bernstein, H. Judd, R. Hanisch, M. Pike and B. Henderson: Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst, 76(1), 45-8 (1986)

  • [35]E. D. Crawford: Epidemiology of prostate cancer. Urology, 62(6 Suppl 1), 3-12 (2003)

  • [36]A. H. Wu, A. S. Whittemore, L. N. Kolonel, E. M. John, R. P. Gallagher, D. W. West, J. Hankin, C. Z. Teh, D. M. Dreon and R. S. Paffenbarger, Jr.: Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev, 4(7), 735-41 (1995)

  • [37]P. H. Gann, C. H. Hennekens, J. Ma, C. Longcope and M. J. Stampfer: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst, 88(16), 1118-26 (1996)

  • [38]R. Heikkila, K. Aho, M. Heliovaara, M. Hakama, J. Marniemi, A. Reunanen and P. Knekt: Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer, 86(2), 312-5 (1999)

  • [39]V. D. Ding, D. E. Moller, W. P. Feeney, V. Didolkar, A. M. Nakhla, L. Rhodes, W. Rosner and R. G. Smith: Sex hormone-binding globulin mediates prostate androgen receptor action via a novel signaling pathway. Endocrinology, 139(1), 213-8 (1998)

  • [40]D. J. Hryb, M. S. Khan, N. A. Romas and W. Rosner: The control of the interaction of sex hormone-binding globulin with its receptor by steroid hormones. J Biol Chem, 265(11), 6048-54 (1990)

  • [41]T. Usui, T. Ishibe, H. Nakatsu, M. Nakahara, H. Nihira and Y. Miyachi: Immunohistochemical localization of testosterone-estradiol-binding globulin in a clinically hormone-independent prostatic carcinoma. Urol Int, 38(1), 16-8 (1983)

  • [42]S. M. Kahn, D. J. Hryb, A. M. Nakhla, N. A. Romas and W. Rosner: Sex hormone-binding globulin is synthesized in target cells. J Endocrinol, 175(1), 113-20 (2002)

  • [43]I. Piras, A. Falchi, P. Moral, A. Melis, L. Giovannoni, G. Paoli, C. Calo, G. Vona and L. Varesi: Frequencies of promoter pentanucleotide (TTTTA)n of CYP11A gene in European and North African populations. Genet Test, 12(1), 93-6 (2008)

  • [44]T. Kumazawa, N. Tsuchiya, L. Wang, K. Sato, T. Kamoto, O. Ogawa, A. Nakamura, T. Kato and T. Habuchi: Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int J Cancer, 110(1), 140-4 (2004)

  • [45]L. Tang, S. Yao, C. Till, P. J. Goodman, C. M. Tangen, Y. Wu, A. R. Kristal, E. A. Platz, M. L. Neuhouser, F. Z. Stanczyk, J. K. Reichardt, R. M. Santella, A. Hsing, A. Hoque, S. M. Lippman, I. M. Thompson and C. B. Ambrosone: Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis, 32(10), 1500-6 (2011)

  • [46]J. Picado-Leonard and W. L. Miller: Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA, 6(5), 439-48 (1987)

  • [47]A. H. Carey, D. Waterworth, K. Patel, D. White, J. Little, P. Novelli, S. Franks and R. Williamson: Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet, 3(10), 1873-6 (1994)

  • [48]R. M. Lunn, D. A. Bell, J. L. Mohler and J. A. Taylor: Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis, 20(9), 1727-31 (1999)

  • [49]A. Gsur, G. Bernhofer, S. Hinteregger, G. Haidinger, G. Schatzl, S. Madersbacher, M. Marberger, C. Vutuc and M. Micksche: A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer, 87(3), 434-7 (2000)

  • [50]Y. Yamada, M. Watanabe, M. Murata, M. Yamanaka, Y. Kubota, H. Ito, T. Katoh, J. Kawamura, R. Yatani and T. Shiraishi: Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer, 92(5), 683-6 (2001)

  • [51]C. A. Haiman, M. J. Stampfer, E. Giovannucci, J. Ma, N. E. Decalo, P. W. Kantoff and D. J. Hunter: The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev, 10(7), 743-8 (2001)

  • [52]R. A. Kittles, R. K. Panguluri, W. Chen, A. Massac, C. Ahaghotu, A. Jackson, F. Ukoli, L. Adams-Campbell, W. Isaacs and G. M. Dunston: Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev, 10(9), 943-7 (2001)

  • [53]J. L. Stanford, E. A. Noonan, L. Iwasaki, S. Kolb, R. B. Chadwick, Z. Feng and E. A. Ostrander: A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 11(3), 243-7 (2002)

  • [54]B. Chang, S. L. Zheng, S. D. Isaacs, K. E. Wiley, J. D. Carpten, G. A. Hawkins, E. R. Bleecker, P. C. Walsh, J. M. Trent, D. A. Meyers, W. B. Isaacs and J. Xu: Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int J Cancer, 95(6), 354-9 (2001)

  • [55]A. G. Latil, R. Azzouzi, G. S. Cancel, E. C. Guillaume, B. Cochan-Priollet, P. L. Berthon and O. Cussenot: Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer, 92(5), 1130-7 (2001)

  • [56]M. Wadelius, A. O. Andersson, J. E. Johansson, C. Wadelius and E. Rane: Prostate cancer associated with CYP17 genotype. Pharmacogenetics, 9(5), 635-9 (1999)

  • [57]T. Habuchi, Z. Liqing, T. Suzuki, R. Sasaki, N. Tsuchiya, H. Tachiki, N. Shimoda, S. Satoh, K. Sato, Y. Kakehi, T. Kamoto, O. Ogawa and T. Kato: Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res, 60(20), 5710-3 (2000)

  • [58]C. Ntais, A. Polycarpou and J. P. Ioannidis: Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 12(2), 120-6 (2003)

  • [59]H. S. Feigelson, R. McKean-Cowdin, M. C. Pike, G. A. Coetzee, L. N. Kolonel, A. M. Nomura, L. Le Marchand and B. E. Henderson: Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res, 59(16), 3908-10 (1999)

  • [60]R. K. Ross, L. Bernstein, R. A. Lobo, H. Shimizu, F. Z. Stanczyk, M. C. Pike and B. E. Henderson: 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339(8798), 887-9 (1992)

  • [61]A. E. Thigpen, R. I. Silver, J. M. Guileyardo, M. L. Casey, J. D. McConnell and D. W. Russell: Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest, 92(2), 903-10 (1993)

  • [62]D. P. Lookingbill, L. M. Demers, C. Wang, A. Leung, R. S. Rittmaster and R. J. Santen: Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab, 72(6), 1242-8 (1991)

  • [63]J. K. Reichardt, N. Makridakis, B. E. Henderson, M. C. Yu, M. C. Pike and R. K. Ross: Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res, 55(18), 3973-5 (1995)

  • [64]J. E. Montie and K. J. Pienta: Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology, 43(6), 892-9 (1994)

  • [65]R. Anwar, S. G. Gilbey, J. P. New and A. F. Markham: Male pseudohermaphroditism resulting from a novel mutation in the human steroid 5 alpha-reductase type 2 gene (SRD5A2). Mol Pathol, 50(1), 51-2 (1997)

  • [66]N. Makridakis, R. K. Ross, M. C. Pike, L. Chang, F. Z. Stanczyk, L. N. Kolonel, C. Y. Shi, M. C. Yu, B. E. Henderson and J. K. Reichardt: A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res, 57(6), 1020-2 (1997)

  • [67]N. M. Makridakis, R. K. Ross, M. C. Pike, L. E. Crocitto, L. N. Kolonel, C. L. Pearce, B. E. Henderson and J. K. Reichardt: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet, 354(9183), 975-8 (1999)

  • [68]J. Simard, F. Durocher, F. Mebarki, C. Turgeon, R. Sanchez, Y. Labrie, J. Couet, C. Trudel, E. Rheaume, Y. Morel, V. Luu-The and F. Labrie: Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. J Endocrinol, 150 Suppl, S189-207 (1996)

  • [69]L. Wang, E. Salavaggione, L. Pelleymounter, B. Eckloff, E. Wieben and R. Weinshilboum: Human 3beta-hydroxysteroid dehydrogenase types 1 and 2: Gene sequence variation and functional genomics. J Steroid Biochem Mol Biol, 107(1-2), 88-99 (2007)

  • [70]H. Verreault, I. Dufort, J. Simard, F. Labrie and V. Luu-The: Dinucleotide repeat polymorphisms in the HSD3B2 gene. Hum Mol Genet, 3(2), 384 (1994)

  • [71]C. Neslund-Dudas, C. H. Bock, K. Monaghan, N. L. Nock, J. J. Yang, A. Rundle, D. Tang and B. A. Rybicki: SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate, 67(15), 1654-63 (2007)

  • [72]S. A. Devgan, B. E. Henderson, M. C. Yu, C. Y. Shi, M. C. Pike, R. K. Ross and J. K. Reichardt: Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate, 33(1), 9-12 (1997)

  • [73]B. L. Chang, S. L. Zheng, G. A. Hawkins, S. D. Isaacs, K. E. Wiley, A. Turner, J. D. Carpten, E. R. Bleecker, P. C. Walsh, J. M. Trent, D. A. Meyers, W. B. Isaacs and J. Xu: Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res, 62(6), 1784-9 (2002)

  • [74]A. L. Eriksson, M. Lorentzon, L. Vandenput, F. Labrie, M. Lindersson, A. C. Syvanen, E. S. Orwoll, S. R. Cummings, J. M. Zmuda, O. Ljunggren, M. K. Karlsson, D. Mellstrom and C. Ohlsson: Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men. J Clin Endocrinol Metab, 94(3), 1033-41 (2009)

  • [75]R. C. Travis, F. Schumacher, J. N. Hirschhorn, P. Kraft, N. E. Allen, D. Albanes, G. Berglund, S. I. Berndt, H. Boeing, H. B. Bueno-de-Mesquita, E. E. Calle, S. Chanock, A. M. Dunning, R. Hayes, H. S. Feigelson, J. M. Gaziano, E. Giovannucci, C. A. Haiman, B. E. Henderson, R. Kaaks, L. N. Kolonel, J. Ma, L. Rodriguez, E. Riboli, M. Stampfer, D. O. Stram, M. J. Thun, A. Tjonneland, D. Trichopoulos, P. Vineis, J. Virtamo, L. Le Marchand and D. J. Hunter: CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev, 18(10), 2734-44 (2009)

  • [76]T. Sonoda, H. Suzuki, M. Mori, T. Tsukamoto, A. Yokomizo, S. Naito, K. Fujimoto, Y. Hirao, N. Miyanaga and H. Akaza: Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men. Eur J Cancer Prev, 19(2), 131-7 (2010)

  • [77]Y. C. Huang, M. Chen, M. W. Lin, M. Y. Chung, Y. H. Chang, W. J. Huang, T. T. Wu, J. M. Hsu, S. Yang and Y. M. Chen: CYP19 TCT tri-nucleotide Del/Del genotype is a susceptibility marker for prostate cancer in a Taiwanese population. Urology, 69(5), 996-1000 (2007)

  • [78]K. Onsory, R. C. Sobti, A. I. Al-Badran, M. Watanabe, T. Shiraishi, A. Krishan, H. Mohan and P. Kaur: Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. Mol Cell Biochem, 314(1-2), 25-35 (2008)

  • [79]N. Mononen, E. H. Seppala, P. Duggal, V. Autio, T. Ikonen, P. Ellonen, J. Saharinen, J. Saarela, M. Vihinen, T. L. Tammela, O. Kallioniemi, J. E. Bailey-Wilson and J. Schleutker: Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res, 66(2), 743-7 (2006)

  • [80]J. Beuten, J. A. Gelfond, J. L. Franke, K. S. Weldon, A. C. Crandall, T. L. Johnson-Pais, I. M. Thompson and R. J. Leach: Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 18(6), 1869-80 (2009)

  • [81]F. Modugno, J. L. Weissfeld, D. L. Trump, J. M. Zmuda, P. Shea, J. A. Cauley and R. E. Ferrell: Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res, 7(10), 3092-6 (2001)

  • [82]K. Gellner, R. Eiselt, E. Hustert, H. Arnold, I. Koch, M. Haberl, C. J. Deglmann, O. Burk, D. Buntefuss, S. Escher, C. Bishop, H. G. Koebe, U. Brinkmann, H. P. Klenk, K. Kleine, U. A. Meyer and L. Wojnowski: Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics, 11(2), 111-21 (2001)

  • [83]P. Kraft, P. Pharoah, S. J. Chanock, D. Albanes, L. N. Kolonel, R. B. Hayes, D. Altshuler, G. Andriole, C. Berg, H. Boeing, N. P. Burtt, B. Bueno-de-Mesquita, E. E. Calle, H. Cann, F. Canzian, Y. C. Chen, D. E. Crawford, A. M. Dunning, H. S. Feigelson, M. L. Freedman, J. M. Gaziano, E. Giovannucci, C. A. Gonzalez, C. A. Haiman, G. Hallmans, B. E. Henderson, J. N. Hirschhorn, D. J. Hunter, R. Kaaks, T. Key, L. Le Marchand, J. Ma, K. Overvad, D. Palli, M. C. Pike, E. Riboli, C. Rodriguez, W. V. Setiawan, M. J. Stampfer, D. O. Stram, G. Thomas, M. J. Thun, R. Travis, A. Trichopoulou, J. Virtamo and S. Wacholder: Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet, 1(5), e68 (2005)

  • [84]T. Sun, W. K. Oh, S. Jacobus, M. Regan, M. Pomerantz, M. L. Freedman, G. S. Lee and P. W. Kantoff: The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila), 4(12), 2044-50 (2011)

  • [85]G. R. Cunningham, C. M. Ashton, J. F. Annegers, J. Souchek, M. Klima and B. Miles: Familial aggregation of prostate cancer in African-Americans and white Americans. Prostate, 56(4), 256-62 (2003)

  • [86]K. Margiotti, E. Kim, C. L. Pearce, E. Spera, G. Novelli and J. K. Reichardt: Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate, 53(1), 65-8 (2002)

  • [87]S. Lindstrom, S. L. Zheng, F. Wiklund, B. A. Jonsson, H. O. Adami, K. A. Balter, A. J. Brookes, J. Sun, B. L. Chang, W. Liu, G. Li, W. B. Isaacs, J. Adolfsson, H. Gronberg and J. Xu: Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate, 66(16), 1729-43 (2006)

  • [88]K. K. Rasiah, M. Gardiner-Garden, E. J. Padilla, G. Moller, J. G. Kench, M. C. Alles, S. A. Eggleton, P. D. Stricker, J. Adamski, R. L. Sutherland, S. M. Henshall and V. M. Hayes: HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol Cell Endocrinol, 301(1-2), 89-96 (2009)

  • [89]R. W. Ross, W. K. Oh, W. Xie, M. Pomerantz, M. Nakabayashi, O. Sartor, M. E. Taplin, M. M. Regan, P. W. Kantoff and M. Freedman: Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol, 26(6), 842-7 (2008)

  • [90]J. Jakobsson, E. Palonek, M. Lorentzon, C. Ohlsson, A. Rane and L. Ekstrom: A novel polymorphism in the 17beta-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase 1C3) gene is associated with lower serum testosterone levels in caucasian men. Pharmacogenomics J, 7(4), 282-9 (2007)

  • [91]J. J. Schulze, H. Karypidis and L. Ekstrom: Basal and Regulatory Promoter Studies of the AKR1C3 Gene in Relation to Prostate Cancer. Front Pharmacol, 3, 151 (2012)

  • [92]J. W. Lampe, J. Bigler, A. C. Bush and J. D. Potter: Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol Biomarkers Prev, 9(3), 329-33 (2000)

  • [93]H. Okugi, H. Nakazato, H. Matsui, N. Ohtake, S. Nakata and K. Suzuki: Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population. Cancer Detect Prev, 30(3), 262-8 (2006)

  • [94]A. Gsur, M. Preyer, G. Haidinger, G. Schatzl, S. Madersbacher, M. Marberger, C. Vutuc and M. Micksche: A polymorphism in the UDP-Glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 11(5), 497-8 (2002)

  • [95]A. H. Heald, F. Ivison, S. G. Anderson, K. Cruickshank, I. Laing and J. M. Gibson: Significant ethnic variation in total and free testosterone concentration. Clin Endocrinol (Oxf), 58(3), 262-6 (2003)

  • [96]A. W. Roddam, N. E. Allen, P. Appleby and T. J. Key: Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst, 100(3), 170-83 (2008)

  • [97]S. G. Power, W. P. Bocchinfuso, M. Pallesen, S. Warmels-Rodenhiser, H. Van Baelen and G. L. Hammond: Molecular analyses of a human sex hormone-binding globulin variant: evidence for an additional carbohydrate chain. J Clin Endocrinol Metab, 75(4), 1066-70 (1992)

  • [98]Y. L. Low, J. I. Taylor, P. B. Grace, A. A. Mulligan, A. A. Welch, S. Scollen, A. M. Dunning, R. N. Luben, K. T. Khaw, N. E. Day, N. J. Wareham and S. A. Bingham: Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer, 56(1), 31-9 (2006)

  • [99]D. L. Winter, A. L. Hanlon, S. L. Raysor, D. Watkins-Bruner, W. H. Pinover, G. E. Hanks and J. V. Tricoli: Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer. Urology, 58(4), 614-8 (2001)

  • [100]R. W. deVere White, A. D. Deitch, A. G. Jackson, R. Gandour-Edwards, J. Marshalleck, S. E. Soares, S. N. Toscano, J. M. Lunetta and S. L. Stewart: Racial differences in clinically localized prostate cancers of black and white men. J Urol, 159(6), 1979-82; discussion 1982-3 (1998)

  • [101]E. C. Pietsch, O. Humbey and M. E. Murphy: Polymorphisms in the p53 pathway. Oncogene, 25(11), 1602-11 (2006)

  • [102]Y. Haupt, R. Maya, A. Kazaz and M. Oren: Mdm2 promotes the rapid degradation of p53. Nature, 387(6630), 296-9 (1997)

  • [103]M. H. Kubbutat, S. N. Jones and K. H. Vousden: Regulation of p53 stability by Mdm2. Nature, 387(6630), 299-303 (1997)

  • [104]G. L. Bond, W. Hu and A. J. Levine: MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets, 5(1), 3-8 (2005)

  • [105]I. Osman, M. Drobnjak, M. Fazzari, J. Ferrara, H. I. Scher and C. Cordon-Cardo: Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res, 5(8), 2082-8 (1999)

  • [106]K. R. Leite, M. F. Franco, M. Srougi, L. J. Nesrallah, A. Nesrallah, R. G. Bevilacqua, E. Darini, C. M. Carvalho, M. I. Meirelles, I. Santana and L. H. Camara-Lopes: Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol, 14(5), 428-36 (2001)

  • [107]L. Y. Khor, M. Desilvio, T. Al-Saleem, M. E. Hammond, D. J. Grignon, W. Sause, M. Pilepich, P. Okunieff, H. Sandler and A. Pollack: MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer, 104(5), 962-7 (2005)

  • [108]R. Bianco, R. Caputo, R. Caputo, V. Damiano, S. De Placido, C. Ficorella, S. Agrawal, A. R. Bianco, F. Ciardiello and G. Tortora: Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clin Cancer Res, 10(14), 4858-64 (2004)

  • [109]H. Wang, D. Yu, S. Agrawal and R. Zhang: Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate, 54(3), 194-205 (2003)

  • [110]Z. Zhang, M. Li, H. Wang, S. Agrawal and R. Zhang: Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A, 100(20), 11636-41 (2003)

  • [111]G. L. Bond, C. Menin, R. Bertorelle, P. Alhopuro, L. A. Aaltonen and A. J. Levine: MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet, 43(12), 950-2 (2006)

  • [112]H. Lind, S. Zienolddiny, P. O. Ekstrom, V. Skaug and A. Haugen: Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer, 119(3), 718-21 (2006)

  • [113]C. Menin, M. C. Scaini, G. L. De Salvo, M. Biscuola, M. Quaggio, G. Esposito, C. Belluco, M. Montagna, S. Agata, E. D’Andrea, D. Nitti, A. Amadori and R. Bertorelle: Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst, 98(4), 285-8 (2006)

  • [114]P. Alhopuro, S. K. Ylisaukko-Oja, W. J. Koskinen, P. Bono, J. Arola, H. J. Jarvinen, J. P. Mecklin, T. Atula, R. Kontio, A. A. Makitie, S. Suominen, I. Leivo, P. Vahteristo, L. M. Aaltonen and L. A. Aaltonen: The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet, 42(9), 694-8 (2005)

  • [115]R. I. Yarden, E. Friedman, S. Metsuyanim, T. Olender, E. Ben-Asher and M. Z. Papa: MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat, 111(3), 497-504 (2008)

  • [116]G. Wang, E. F. Firoz, A. Rose, E. Blochin, P. Christos, D. Pollens, M. Mazumdar, W. Gerald, C. Oddoux, P. Lee and I. Osman: MDM2 expression and regulation in prostate cancer racial disparity. Int J Clin Exp Pathol, 2(4), 353-60 (2009)

  • [117]C. M. Zeigler-Johnson, A. H. Walker, B. Mancke, E. Spangler, M. Jalloh, S. McBride, A. Deitz, S. B. Malkowicz, D. Ofori-Adjei, S. M. Gueye and T. R. Rebbeck: Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered, 54(1), 13-21 (2002)

  • [118]D. C. Miller, S. L. Zheng, R. L. Dunn, A. V. Sarma, J. E. Montie, E. M. Lange, D. A. Meyers, J. Xu and K. A. Cooney: Germ-line mutations of the macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-American men. Cancer Res, 63(13), 3486-9 (2003)

  • [119]I. Oakley-Girvan, D. Feldman, T. R. Eccleshall, R. P. Gallagher, A. H. Wu, L. N. Kolonel, J. Halpern, R. R. Balise, D. W. West, R. S. Paffenbarger, Jr. and A. S. Whittemore: Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev, 13(8), 1325-30 (2004)

  • [120]K. R. Monroe, M. C. Yu, L. N. Kolonel, G. A. Coetzee, L. R. Wilkens, R. K. Ross and B. E. Henderson: Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med, 1(8), 827-9 (1995)

  • [121]S. I. Bastacky, K. J. Wojno, P. C. Walsh, M. J. Carmichael and J. I. Epstein: Pathological features of hereditary prostate cancer. J Urol, 153(3 Pt 2), 987-92 (1995)

  • [122]D. Mirchandani, J. Zheng, G. J. Miller, A. K. Ghosh, D. K. Shibata, R. J. Cote and P. Roy-Burman: Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol, 147(1), 92-101 (1995)

  • [123]J. Qian, D. G. Bostwick, S. Takahashi, T. J. Borell, J. F. Herath, M. M. Lieber and R. B. Jenkins: Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res, 55(22), 5408-14 (1995)

  • [124]W. A. Sakr, D. J. Grignon, J. D. Crissman, L. K. Heilbrun, B. J. Cassin, J. J. Pontes and G. P. Haas: High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249cases. In vivo, 8(3), 439-43 (1994)

  • [125]T. R. Rebbeck: Genetics, disparities, and prostate cancer. LDI Issue Brief, 10(7), 1-4 (2005)

  • [126]J. Xu, S. L. Zheng, G. A. Hawkins, D. A. Faith, B. Kelly, S. D. Isaacs, K. E. Wiley, B. Chang, C. M. Ewing, P. Bujnovszky, J. D. Carpten, E. R. Bleecker, P. C. Walsh, J. M. Trent, D. A. Meyers and W. B. Isaacs: Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. Am J Hum Genet, 69(2), 341-50 (2001)

  • [127]M. Gibbs, J. L. Stanford, G. P. Jarvik, M. Janer, M. Badzioch, M. A. Peters, E. L. Goode, S. Kolb, L. Chakrabarti, M. Shook, R. Basom, E. A. Ostrander and L. Hood: A genomic scan of families with prostate cancer identifies multiple regions of interest. Am J Hum Genet, 67(1), 100-9 (2000)

  • [128]M. R. Emmert-Buck, C. D. Vocke, R. O. Pozzatti, P. H. Duray, S. B. Jennings, C. D. Florence, Z. Zhuang, D. G. Bostwick, L. A. Liotta and W. M. Linehan: Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res, 55(14), 2959-62 (1995)

  • [129]C. D. Vocke, R. O. Pozzatti, D. G. Bostwick, C. D. Florence, S. B. Jennings, S. E. Strup, P. H. Duray, L. A. Liotta, M. R. Emmert-Buck and W. M. Linehan: Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res, 56(10), 2411-6 (1996)

  • [130]H. Zitzelsberger, D. Engert, A. Walch, U. Kulka, M. Aubele, H. Hofler, M. Bauchinger and M. Werner: Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer, 84(2), 202-8 (2001)

  • [131]R. S. Verma, M. Manikal, R. A. Conte and C. J. Godec: Chromosomal basis of adenocarcinoma of the prostate. Cancer Invest, 17(6), 441-7 (1999)

  • [132]R. Bookstein: Tumor suppressor genes in prostatic oncogenesis. J Cell Biochem Suppl, 19, 217-23 (1994)

  • [133]J. A. Kalapurakal, A. N. Jacob, P. Y. Kim, D. D. Najjar, Y. C. Hsieh, P. Ginsberg, I. Daskal, S. O. Asbell and R. P. Kandpal: Racial differences in prostate cancer related to loss of heterozygosity on chromosome 8p12-23. Int J Radiat Oncol Biol Phys, 45(4), 835-40 (1999)

  • [134]D. P. BarTel: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116(2), 281-97 (2004)

  • [135]A. M. Denli, B. B. Tops, R. H. Plasterk, R. F. Ketting and G. J. Hannon: Processing of primary microRNAs by the Microprocessor complex. Nature, 432(7014), 231-5 (2004)

  • [136]G. A. Calin, C. Sevignani, C. D. Dumitru, T. Hyslop, E. Noch, S. Yendamuri, M. Shimizu, S. Rattan, F. Bullrich, M. Negrini and C. M. Croce: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A, 101(9), 2999-3004 (2004)

  • [137]J. Lu, G. Getz, E. A. Miska, E. Alvarez-Saavedra, J. Lamb, D. Peck, A. Sweet-Cordero, B. L. Ebert, R. H. Mak, A. A. Ferrando, J. R. Downing, T. Jacks, H. R. Horvitz and T. R. Golub: MicroRNA expression profiles classify human cancers. Nature, 435(7043), 834-8 (2005)

  • [138]M. V. Iorio, M. Ferracin, C. G. Liu, A. Veronese, R. Spizzo, S. Sabbioni, E. Magri, M. Pedriali, M. Fabbri, M. Campiglio, S. Menard, J. P. Palazzo, A. Rosenberg, P. Musiani, S. Volinia, I. Nenci, G. A. Calin, P. Querzoli, M. Negrini and C. M. Croce: MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65(16), 7065-70 (2005)

  • [139]C. G. Liu, G. A. Calin, B. Meloon, N. Gamliel, C. Sevignani, M. Ferracin, C. D. Dumitru, M. Shimizu, S. Zupo, M. Dono, H. Alder, F. Bullrich, M. Negrini and C. M. Croce: An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A, 101(26), 9740-4 (2004)

  • [140]Y. Akao, Y. Nakagawa and T. Naoe: MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep, 16(4), 845-50 (2006)

  • [141]Y. Hayashita, H. Osada, Y. Tatematsu, H. Yamada, K. Yanagisawa, S. Tomida, Y. Yatabe, K. Kawahara, Y. Sekido and T. Takahashi: Apolycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res, 65(21), 9628-32 (2005)

  • [142]L. He, J. M. Thomson, M. T. Hemann, E. Hernando-Monge, D. Mu, S. Goodson, S. Powers, C. Cordon-Cardo, S. W. Lowe, G. J. Hannon and S. M. Hammond: A microRNA polycistron as a potential human oncogene. Nature, 435(7043), 828-33 (2005)

  • [143]P. M. Voorhoeve, C. le Sage, M. Schrier, A. J. Gillis, H. Stoop, R. Nagel, Y. P. Liu, J. van Duijse, J. Drost, A. Griekspoor, E. Zlotorynski, N. Yabuta, G. De Vita, H. Nojima, L. H. Looijenga and R. Agami: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell, 124(6), 1169-81 (2006)

  • [144]M. L. Si, S. Zhu, H. Wu, Z. Lu, F. Wu and Y. Y. Mo: miR-21-mediated tumor growth. Oncogene, 26(19), 2799-803 (2007)

  • [145]T. Wang, X. Zhang, L. Obijuru, J. Laser, V. Aris, P. Lee, K. Mittal, P. Soteropoulos and J. J. Wei: A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer, 46(4), 336-47 (2007)

  • [146]G. A. Calin and C. M. Croce: MicroRNA signatures in human cancers. Nat Rev Cancer, 6(11), 857-66 (2006)

  • [147]K. M. Rahman and W. A. Sakr: The therapeutic value of natural agents to treat miRNA targeted breast cancer in African-American and Caucasian-American women. Curr Drug Targets, 13(14), 1917-25 (2012)

  • [148]T. J. Polascik, J. E. Oesterling and A. W. Partin: Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol, 162(2), 293-306 (1999)

  • [149]J. Oh, J. W. Colberg, D. K. Ornstein, E. T. Johnson, D. Chan, K. S. Virgo and F. E. Johnson: Current followup strategies after radical prostatectomy: a survey of American Urological Association urologists. J Urol, 161(2), 520-3 (1999)

  • [150]S. B. Zeliadt, D. F. Penson, P. C. Albertsen, J. Concato and R. D. Etzioni: Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer, 98(3), 496-503 (2003)

  • [151]A. B. Mariotto, R. Etzioni, M. Krapcho and E. J. Feuer: Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer, 109(9), 1877-86 (2007)

  • [152]W. M. Xue, G. A. Coetzee, R. K. Ross, R. Irvine, L. Kolonel, B. E. Henderson and S. A. Ingles: Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev, 10(6), 575-9 (2001)

  • [153]R. Deka, S. Guangyun, J. Wiest, D. Smelser, S. Chunhua, Y. Zhong and R. Chakraborty: Patterns of instability of expanded CAG repeats at the ERDA1 locus in general populations. Am J Hum Genet, 65(1), 192-8 (1999)

  • [154]A. Shibata and A. S. Whittemore: Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Prostate, 32(1), 65-72 (1997)

  • [155]J. R. Smith, D. Freije, J. D. Carpten, H. Gronberg, J. Xu, S. D. Isaacs, M. J. Brownstein, G. S. Bova, H. Guo, P. Bujnovszky, D. R. Nusskern, J. E. Damber, A. Bergh, M. Emanuelsson, O. P. Kallioniemi, J. Walker-Daniels, J. E. Bailey-Wilson, T. H. Beaty, D. A. Meyers, P. C. Walsh, F. S. Collins, J. M. Trent and W. B. Isaacs: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science, 274(5291), 1371-4 (1996)

  • [156]J. Xu, D. Meyers, D. Freije, S. Isaacs, K. Wiley, D. Nusskern, C. Ewing, E. Wilkens, P. Bujnovszky, G. S. Bova, P. Walsh, W. Isaacs, J. Schleutker, M. Matikainen, T. Tammela, T. Visakorpi, O. P. Kallioniemi, R. Berry, D. Schaid, A. French, S. McDonnell, J. Schroeder, M. Blute, S. Thibodeau, H. Gronberg, M. Emanuelsson, J. E. Damber, A. Bergh, B. A. Jonsson, J. Smith, J. Bailey-Wilson, J. Carpten, D. Stephan, E. Gillanders, I. Amundson, T. Kainu, D. Freas-Lutz, A. Baffoe-Bonnie, A. Van Aucken, R. Sood, F. Collins, M. Brownstein and J. Trent: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet, 20(2), 175-9 (1998)

  • [157]J. Xu, S. L. Zheng, B. Chang, J. R. Smith, J. D. Carpten, O. C. Stine, S. D. Isaacs, K. E. Wiley, L. Henning, C. Ewing, P. Bujnovszky, E. R. Bleeker, P. C. Walsh, J. M. Trent, D. A. Meyers and W. B. Isaacs: Linkage of prostate cancer susceptibility loci to chromosome 1. Hum Genet, 108(4), 335-45 (2001)

  • [158]S. L. Zheng, J. Xu, S. D. Isaacs, K. Wiley, B. Chang, E. R. Bleecker, P. C. Walsh, J. M. Trent, D. A. Meyers and W. B. Isaacs: Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. Hum Genet, 108(5), 430-5 (2001)

  • [159]J. Xu, S. L. Zheng, J. D. Carpten, N. N. Nupponen, C. M. Robbins, J. Mestre, T. Y. Moses, D. A. Faith, B. D. Kelly, S. D. Isaacs, K. E. Wiley, C. M. Ewing, P. Bujnovszky, B. Chang, J. Bailey-Wilson, E. R. Bleecker, P. C. Walsh, J. M. Trent, D. A. Meyers and W. B. Isaacs: Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet, 68(4), 901-11 (2001)

  • [160]G. Gong, I. Oakley-Girvan, A. H. Wu, L. N. Kolonel, E. M. John, D. W. West, A. Felberg, R. P. Gallagher and A. S. Whittemore: Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada. Cancer Causes Control, 13(5), 471-82 (2002)

  • [161]C. Ahaghotu, A. Baffoe-Bonnie, R. Kittles, C. Pettaway, I. Powell, C. Royal, H. Wang, S. Vijayakumar, J. Bennett, G. Hoke, T. Mason, J. Bailey-Wilson, W. Boykin, K. Berg, J. Carpten, S. Weinrich, J. Trent, G. Dunston and F. Collins: Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study. Prostate Cancer Prostatic Dis, 7(2), 165-9 (2004)

  • [162]W. M. Brown, E. M. Lange, H. Chen, S. L. Zheng, B. Chang, K. E. Wiley, S. D. Isaacs, P. C. Walsh, W. B. Isaacs, J. Xu and K. A. Cooney: Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci. Br J Cancer, 90(2), 510-4 (2004)

  • [163]J. Xu, S. L. Zheng, A. Komiya, J. C. Mychaleckyj, S. D. Isaacs, J. J. Hu, D. Sterling, E. M. Lange, G. A. Hawkins, A. Turner, C. M. Ewing, D. A. Faith, J. R. Johnson, H. Suzuki, P. Bujnovszky, K. E. Wiley, A. M. DeMarzo, G. S. Bova, B. Chang, M. C. Hall, D. L. McCullough, A. W. Partin, V. S. Kassabian, J. D. Carpten, J. E. Bailey-Wilson, J. M. Trent, J. Ohar, E. R. Bleecker, P. C. Walsh, W. B. Isaacs and D. A. Meyers: Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet, 32(2), 321-5 (2002)

  • [164]J. Xu, S. L. Zheng, A. Komiya, J. C. Mychaleckyj, S. D. Isaacs, B. Chang, A. R. Turner, C. M. Ewing, K. E. Wiley, G. A. Hawkins, E. R. Bleecker, P. C. Walsh, D. A. Meyers and W. B. Isaacs: Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet, 72(1), 208-12 (2003)

  • [165]G. Yang, J. Addai, M. Ittmann, T. M. Wheeler and T. C. Thompson: Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res, 6(9), 3430-3 (2000)

  • [166]V. Mouraviev, L. Li, S. A. Tahir, G. Yang, T. M. Timme, A. Goltsov, C. Ren, T. Satoh, T. M. Wheeler, M. M. Ittmann, B. J. Miles, R. J. Amato, D. Kadmon and T. C. Thompson: The role of caveolin-1 in androgen insensitive prostate cancer. J Urol, 168(4 Pt 1), 1589-96 (2002)

  • [167]D. J. Waxman, C. Attisano, F. P. Guengerich and D. P. Lapenson: Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys, 263(2), 424-36 (1988)

  • [168]D. J. Waxman, D. P. Lapenson, T. Aoyama, H. V. Gelboin, F. J. Gonzalez and K. Korzekwa: Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys, 290(1), 160-6 (1991)

  • [169]V. Ozdemir, W. Kalow, B. K. Tang, A. D. Paterson, S. E. Walker, L. Endrenyi and A. D. Kashuba: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics, 10(5), 373-88 (2000)

  • [170]S. J. Plummer, D. V. Conti, P. L. Paris, A. P. Curran, G. Casey and J. S. Witte: CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 12(9), 928-32 (2003)

  • [171]A. Loukola, M. Chadha, S. G. Penn, D. Rank, D. V. Conti, D. Thompson, M. Cicek, B. Love, V. Bivolarevic, Q. Yang, Y. Jiang, D. K. Hanzel, K. Dains, P. L. Paris, G. Casey and J. S. Witte: Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur J Hum Genet, 12(4), 321-32 (2004)

  • [172]I. J. Powell, J. Zhou, Y. Sun, W. A. Sakr, N. P. Patel, L. K. Heilbrun and R. B. Everson: CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol, 172(5 Pt 1), 1848-52 (2004)

  • [173]S. Leskela, E. Honrado, C. Montero-Conde, I. Landa, A. Cascon, R. Leton, P. Talavera, J. M. Cozar, A. Concha, M. Robledo and C. Rodriguez-Antona: Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. Endocr Relat Cancer, 14(3), 645-54 (2007)

  • [174]P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz, P. B. Watkins, A. Daly, S. A. Wrighton, S. D. Hall, P. Maurel, M. Relling, C. Brimer, K. Yasuda, R. Venkataramanan, S. Strom, K. Thummel, M. S. Boguski and E. Schuetz: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 27(4), 383-91 (2001)

  • [175]L. Zhenhua, N. Tsuchiya, S. Narita, T. Inoue, Y. Horikawa, H. Kakinuma, T. Kato, O. Ogawa and T. Habuchi: CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population. Cancer Lett, 225(2), 237-43 (2005)

  • [176]M. H. Vaarala, H. Mattila, P. Ohtonen, T. L. Tammela, T. K. Paavonen and J. Schleutker: The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int J Cancer, 122(11), 2511-6 (2008)

  • [177]T. L. Domanski, C. Finta, J. R. Halpert and P. G. Zaphiropoulos: cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol, 59(2), 386-92 (2001)

  • [178]A. Stone, L. D. Ratnasinghe, G. L. Emerson, R. Modali, T. Lehman, G. Runnells, A. Carroll, W. Carter, S. Barnhart, A. A. Rasheed, G. Greene, D. E. Johnson, C. B. Ambrosone, F. F. Kadlubar and N. P. Lang: CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev, 14(5), 1257-61 (2005)

  • [179]C. Siemes, L. E. Visser, F. H. de Jong, J. W. Coebergh, A. G. Uitterlinden, A. Hofman, B. H. Stricker and R. H. van Schaik: Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study. Steroids, 75(12), 1024-32 (2010)

  • [180]H. L. Ratan, A. Gescher, W. P. Steward and J. K. Mellon: ErbB receptors: possible therapeutic targets in prostate cancer? BJU Int, 92(9), 890-5 (2003)

  • [181]F. M. Sirotnak, M. F. Zakowski, V. A. Miller, H. I. Scher and M. G. Kris: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res, 6(12), 4885-92 (2000)

  • [182]F. M. Sirotnak, Y. She, F. Lee, J. Chen and H. I. Scher: Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res, 8(12), 3870-6 (2002)

  • [183]D. B. Agus, R. W. Akita, W. D. Fox, G. D. Lewis, B. Higgins, P. I. Pisacane, J. A. Lofgren, C. Tindell, D. P. Evans, K. Maiese, H. I. Scher and M. X. Sliwkowski: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell, 2(2), 127-37 (2002)

  • [184]G. Di Lorenzo, G. Tortora, F. P. D’Armiento, G. De Rosa, S. Staibano, R. Autorino, M. D’Armiento, M. De Laurentiis, S. De Placido, G. Catalano, A. R. Bianco and F. Ciardiello: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res, 8(11), 3438-44 (2002)

  • [185]B. Shuch, M. Mikhail, J. Satagopan, P. Lee, H. Yee, C. Chang, C. Cordon-Cardo, S. S. Taneja and I. Osman: Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol, 22(23), 4725-9 (2004)

  • [186]D. A. Douglas, H. Zhong, J. Y. Ro, C. Oddoux, A. D. Berger, M. R. Pincus, J. M. Satagopan, W. L. Gerald, H. I. Scher, P. Lee and I. Osman: Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci, 11, 2518-25 (2006)

  • [187]M. Gibbs, J. L. Stanford, R. A. McIndoe, G. P. Jarvik, S. Kolb, E. L. Goode, L. Chakrabarti, E. F. Schuster, V. A. Buckley, E. L. Miller, S. Brandzel, S. Li, L. Hood and E. A. Ostrander: Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet, 64(3), 776-87 (1999)

  • [188]H. Matsui, K. Suzuki, N. Ohtake, S. Nakata, T. Takeuchi, H. Yamanaka and I. Inoue: Genomewide linkage analysis of familial prostate cancer in the Japanese population. J Hum Genet, 49(1), 9-15 (2004)

  • [189]R. A. Kittles, A. B. Baffoe-Bonnie, T. Y. Moses, C. M. Robbins, C. Ahaghotu, P. Huusko, C. Pettaway, S. Vijayakumar, J. Bennett, G. Hoke, T. Mason, S. Weinrich, J. M. Trent, F. S. Collins, S. Mousses, J. Bailey-Wilson, P. Furbert-Harris, G. Dunston, I. J. Powell and J. D. Carpten: A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet, 43(6), 507-11 (2006)

  • [190]H. Williams, I. J. Powell, S. J. Land, W. A. Sakr, M. R. Hughes, N. P. Patel, L. K. Heilbrun and R. B. Everson: Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy. Prostate, 61(3), 267-75 (2004)

  • [191]I. M. Shui, L. A. Mucci, P. Kraft, R. M. Tamimi, S. Lindstrom, K. L. Penney, K. Nimptsch, B. W. Hollis, N. Dupre, E. A. Platz, M. J. Stampfer and E. Giovannucci: Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst, 104(9), 690-9 (2012)

  • [192]L. B. Signorello, S. M. Williams, W. Zheng, J. R. Smith, J. Long, Q. Cai, M. K. Hargreaves, B. W. Hollis and W. J. Blot: Blood vitamin d levels in relation to genetic estimation of African ancestry. Cancer Epidemiol Biomarkers Prev, 19(9), 2325-31 (2010)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2017Article
Molecular basis for prostate cancer racial disparities
Santosh K. Singh 1, James W. Lillard Jr 1, Rajesh Singh 1,*
Affiliation
Article Info

1 Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, Georgia 30310, USA

Abstract

Prostate cancer (PCa) remains the most common cancer in American men. African-American (AA) men continue to have higher PCa prevalence and mortality rates compared to men in other populations. In addition to socioeconomic factors and lifestyle differences, molecular alterations contribute to this discrepancy. We summarize molecular genetics research results interrelated with the biology of PCa racial disparity. Androgen and androgen receptor (AR) pathways have long been associated with prostate growth. Racial differences have also been found among variants of genes of the enzymes involved in androgen biosynthesis and metabolism. Growth factors and their receptors are a potential cause of the disparity in PCa. Recent molecular and biotechnological approaches in the field of proteomics and genomics will greatly aid the advancement of translational research on racial disparity in PCa, which may help, in finding new prognostic markers and novel therapeutic approaches for the treatment of PCa in AA.

Keywords

  • Prostate Cancer
  • Androgen Receptors (AR)
  • Racial Disparity

References